FILSPARI Drug Patent Profile
✉ Email this page to a colleague
When do Filspari patents expire, and when can generic versions of Filspari launch?
Filspari is a drug marketed by Travere and is included in one NDA. There is one patent protecting this drug.
This drug has twenty-nine patent family members in fourteen countries.
The generic ingredient in FILSPARI is sparsentan. One supplier is listed for this compound. Additional details are available on the sparsentan profile page.
DrugPatentWatch® Generic Entry Outlook for Filspari
Filspari will be eligible for patent challenges on February 17, 2027. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be February 17, 2030. This may change due to patent challenges or generic licensing.
Indicators of Generic Entry
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for FILSPARI?
- What are the global sales for FILSPARI?
- What is Average Wholesale Price for FILSPARI?
Summary for FILSPARI
International Patents: | 29 |
US Patents: | 1 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 39 |
Clinical Trials: | 1 |
Patent Applications: | 59 |
Drug Prices: | Drug price information for FILSPARI |
What excipients (inactive ingredients) are in FILSPARI? | FILSPARI excipients list |
DailyMed Link: | FILSPARI at DailyMed |
![FILSPARI drug patent expirations Drug patent expirations by year for FILSPARI](/p/graph/s/t/FILSPARI-patent-expirations.png)
![Drug Prices for FILSPARI](/p/graph/drug-price/FILSPARI.png)
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for FILSPARI
Generic Entry Date for FILSPARI*:
Constraining patent/regulatory exclusivity:
TO REDUCE PROTEINURIA IN ADULTS WITH PRIMARY IMMUNOGLOBULIN A NEPHROPATHY (IGAN) AT RISK OF RAPID DISEASE PROGRESSION, GENERALLY A URINE PROTEIN-TO-CREATININE RATIO (UPCR) > OR = 1.5 G/G NDA:
Dosage:
TABLET;ORAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Recent Clinical Trials for FILSPARI
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Travere Therapeutics, Inc. | Phase 2 |
US Patents and Regulatory Information for FILSPARI
FILSPARI is protected by one US patents and two FDA Regulatory Exclusivities.
Based on analysis by DrugPatentWatch, the earliest date for a generic version of FILSPARI is ⤷ Sign Up.
This potential generic entry date is based on TO REDUCE PROTEINURIA IN ADULTS WITH PRIMARY IMMUNOGLOBULIN A NEPHROPATHY (IGAN) AT RISK OF RAPID DISEASE PROGRESSION, GENERALLY A URINE PROTEIN-TO-CREATININE RATIO (UPCR) > OR = 1.5 G/G.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
Patents protecting FILSPARI
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF PRIMARY IMMUNOGLOBULIN A NEPHROPATHY (IGAN) IN ADULTS AT RISK OF RAPID DISEASE PROGRESSION
FDA Regulatory Exclusivity protecting FILSPARI
TO REDUCE PROTEINURIA IN ADULTS WITH PRIMARY IMMUNOGLOBULIN A NEPHROPATHY (IGAN) AT RISK OF RAPID DISEASE PROGRESSION, GENERALLY A URINE PROTEIN-TO-CREATININE RATIO (UPCR) > OR = 1.5 G/G
Exclusivity Expiration: ⤷ Sign Up
NEW CHEMICAL ENTITY
Exclusivity Expiration: ⤷ Sign Up
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Travere | FILSPARI | sparsentan | TABLET;ORAL | 216403-001 | Feb 17, 2023 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Travere | FILSPARI | sparsentan | TABLET;ORAL | 216403-002 | Feb 17, 2023 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Travere | FILSPARI | sparsentan | TABLET;ORAL | 216403-001 | Feb 17, 2023 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Travere | FILSPARI | sparsentan | TABLET;ORAL | 216403-001 | Feb 17, 2023 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Travere | FILSPARI | sparsentan | TABLET;ORAL | 216403-002 | Feb 17, 2023 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Travere | FILSPARI | sparsentan | TABLET;ORAL | 216403-002 | Feb 17, 2023 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for FILSPARI
See the table below for patents covering FILSPARI around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Spain | 2636087 | ⤷ Sign Up | |
Spain | 2811342 | ⤷ Sign Up | |
Lithuania | 2732818 | ⤷ Sign Up | |
Cyprus | 1123017 | ⤷ Sign Up | |
European Patent Office | 3222277 | ANTAGONISTE DES RÉCEPTEURS DE L'ENDOTHÉLINE ET DE L'ANGIOTENSINE II À BASE DE BIPHÉNYLSULFONAMIDE POUR TRAITER LA GLOMÉRULOSCLÉROSE ET LA NEPHROPATHIE INDUITE PAR L'IGA (A BIPHENYLSULFONAMIDE ENDOTHELIN AND ANGIOTENSIN II RECEPTOR ANTAGONIST TO TREAT GLOMERULOSCLEROSIS AND IGA-INDUCED NEPHROPATHY) | ⤷ Sign Up |
Denmark | 3222277 | ⤷ Sign Up | |
Hungary | E049450 | ⤷ Sign Up | |
>Country | >Patent Number | >Title | >Estimated Expiration |